New England Journal of Medicine, 2017 Comment on : Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med. 2016 Oct 27;375(17):1638-1648. doi: 10.1056/NEJMoa1609409.
Putzu, Alessandro +2 more
openaire +13 more sources
Use of Levosimendan in Cardiac Anesthesiology [PDF]
Общая реаниматология, 2011 The authors consider the main aspects of the rational use of the novel inotropic drug levosimendan in cardiosurgical patients on the basis of the results of the trials described in the literature and on their own findings in this review.
L. A. Krichevsky +4 more
doaj +2 more sources
The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery [PDF]
Journal of Cardiovascular Development and Disease, 2023 Background: Postoperative myocardial dysfunction following cardiac surgery is a relatively common occurrence. Levosimendan, a calcium sensitizer and inotropic drug, has shown potential in improving outcomes for patients with low preoperative ejection ...
Vasileios Leivaditis +9 more
doaj +3 more sources
Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury? [PDF]
PLoS ONE, 2013 INTRODUCTION: Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver. Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of ...
Peter Onody +11 more
doaj +3 more sources
Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review [PDF]
European Cardiology ReviewCardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated.
Hendri Susilo +5 more
doaj +2 more sources
Strategy for Modelling Nonrandom Missing Data Mechanisms in Observational Studies Using Bayesian Methods [PDF]
, 2012 Observational studies inevitably suffer from nonresponses and missing values. Bayesian full probability modelling provides a flexible approach for analysing such data, allowing a plausible model to be built which can then be adapted to carry out a range ...
Best, Nicky +3 more
core +4 more sources
Influence of timing of Levosimendan administration on outcomes in cardiac surgery
Frontiers in Cardiovascular Medicine, 2023 PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel +13 more
doaj +1 more source
An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. [PDF]
, 2014 BACKGROUND: Organ dysfunction consequent to infection ('severe sepsis') is the leading cause of admission to an intensive care unit (ICU). In both animal models and early clinical studies the calcium channel sensitizer levosimendan has been demonstrated ...
McAuley, Daniel F +44 more
core +1 more source
Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. [PDF]
, 2016 To evaluate if the preoperative administration of levosimendan in patients with right ventricular (RV) dysfunction, pulmonary hypertension, and high perioperative risk would improve cardiac function and would also have a protective effect on renal and ...
Galán-Ortega, Manuel +12 more
core +2 more sources
Frontiers in Cardiovascular Medicine, 2022 BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen +10 more
doaj +1 more source